ATOS spray
Utilizing a combination of two other drugs already approved by the United States Food and Drug Administration (the blood thinner Heparin and the anti-inflammatory N-acetylcysteine), Atossa plans to use AT-H201 to treat a group of 60 mixed healthy and moderately-ill hospitalized COVID-19 patients in a Phase 1/2a placebo-controlled study. Heading into the study, Atossa noted that it believes the drugs being used in combination to form AT-H201 may be as much as "four times more potent" than Gilead Sciences' Remdesivir coronavirus treatment, and "at least 20 times more potent" than the generic malarial medicine Hydroxychloroquine.
Utilizing a combination of two other drugs already approved by the United States Food and Drug Administration (the blood thinner Heparin and the anti-inflammatory N-acetylcysteine), Atossa plans to use AT-H201 to treat a group of 60 mixed healthy and moderately-ill hospitalized COVID-19 patients in a Phase 1/2a placebo-controlled study. Heading into the study, Atossa noted that it believes the drugs being used in combination to form AT-H201 may be as much as "four times more potent" than Gilead Sciences' Remdesivir coronavirus treatment, and "at least 20 times more potent" than the generic malarial medicine Hydroxychloroquine.
